Aculeus Therapeutics
Australia - ParkvilleBiotechnology
Focus: Aculeus Therapeutics is an Australian biotech company focused on immune-modulatory small molecules, operating at mid-cap scale with 501-1000 employees.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Employees
501-1000
Open Jobs
0
About Aculeus Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Aculeus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Pixatimod
NSCLCClinical Trials (1)
NCT05061017Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Phase 2Help build intelligence for Aculeus Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.